Citius Oncology, Inc.
CTOR- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001851484
No open-market purchases or sales by Citius Oncology, Inc. insiders were filed in the last 90 days; 19 institutions reported holding it in 13F filings for Q2 2026, worth $9.20M in total; no superinvestor holds it.
Q3 2024 vs. Q2 2024
How the institutions holding Citius Oncology, Inc. changed between Q2 2024 and Q3 2024.
All holders in Q3 2024All holders in Q2 2024
| Measure | Q2 2024 | Q3 2024 | Change |
|---|---|---|---|
| Holders | 0 | 7 | +7 |
| Shares | 0 | 41.2K | +41.2K |
| Value | $0 | $57.0K | +$57.0K |
New holders (7)
Institutions that held Citius Oncology, Inc. at the end of Q3 2024 but not at the end of Q2 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Yakira Capital Management, Inc. | 15,499 | $21.5K | 0.01% |
| Virtu Financial LLC | 10,291 | $14.0K | 0.00% |
| IFP Advisors, Inc | 8,135 | $11.3K | 0.00% |
| Advisor Group Holdings, Inc. | 5,480 | $7.62K | 0.00% |
| UBS Group AG | 1,632 | $2.27K | 0.00% |
| Bank of America Corp | 160 | $222 | 0.00% |
| Tower Research Capital LLC (TRC) | 41 | $57 | 0.00% |
Sold out (0)
Institutions that held Citius Oncology, Inc. at the end of Q2 2024 and filed for Q3 2024 without it.
None.